Compare OBK & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBK | PHVS |
|---|---|---|
| Founded | 1912 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 2.3B |
| IPO Year | 2018 | 2020 |
| Metric | OBK | PHVS |
|---|---|---|
| Price | $51.15 | $34.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $46.67 | $41.82 |
| AVG Volume (30 Days) | 131.4K | ★ 371.0K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.43 | N/A |
| Revenue Next Year | $5.79 | N/A |
| P/E Ratio | $57.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.13 | $17.24 |
| 52 Week High | $52.00 | $35.33 |
| Indicator | OBK | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 62.40 | 64.71 |
| Support Level | $48.10 | $24.73 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.11 | 1.63 |
| MACD | 0.12 | 0.20 |
| Stochastic Oscillator | 74.10 | 70.36 |
Origin Bancorp Inc is a financial holding company that provides personalized, relationship banking to businesses, municipalities, and personal clients in the communities it serves. The company offers a broad range of financial services and operates more than 56 locations in Dallas/Fort Worth, East Texas, Houston, North Louisiana, Mississippi, South Alabama, and the Florida Panhandle. It also provides insurance agency products and services through its wholly owned insurance agency subsidiary. The company operates in one business segment, community banking, and is mainly engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.